To include your compound in the COVID-19 Resource Center, submit it here.

Azilsartan medoxomil/chlorthalidone: Phase III data

A double-blind, North American Phase III trial in 1,071 patients with moderate to severe hypertension showed that once-daily low- and high-dose combinations of azilsartan medoxomil/chlorthalidone each met the primary endpoint of

Read the full 318 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE